

Stephan Petersenn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2690883/publications.pdf>

Version: 2024-02-01

42
papers

2,935
citations

279798

23
h-index

243625

44
g-index

44
all docs

44
docs citations

44
times ranked

2249
citing authors

#	ARTICLE	IF	CITATIONS
1	A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease. <i>New England Journal of Medicine</i> , 2012, 366, 914-924.	27.0	550
2	European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. <i>European Journal of Endocrinology</i> , 2018, 178, G1-G24.	3.7	387
3	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
4	A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR _{1/2} (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. <i>Clinical Endocrinology</i> , 2007, 66, 859-868.	2.4	202
5	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	5.7	183
6	Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 6378-6385.	7.0	160
7	Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1282-1290.	3.6	146
8	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , 2015, 172, R227-R239.	3.7	114
9	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. <i>Clinical Endocrinology</i> , 2014, 81, 408-417.	2.4	95
10	Medical management of Cushing's disease: what is the future?. <i>Pituitary</i> , 2012, 15, 330-341.	2.9	82
11	Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. <i>European Journal of Endocrinology</i> , 2012, 166, 613-618.	3.7	71
12	Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. <i>European Journal of Endocrinology</i> , 2009, 160, 9-16.	3.7	51
13	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. <i>BMC Endocrine Disorders</i> , 2010, 10, 10.	2.2	48
14	Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. <i>Pituitary</i> , 2014, 17, 132-140.	2.9	43
15	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. <i>European Journal of Endocrinology</i> , 2015, 172, 415-422.	3.7	43
16	Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. <i>Molecular and Cellular Endocrinology</i> , 1999, 157, 75-85.	3.2	33
17	Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. <i>European Journal of Endocrinology</i> , 2020, 182, 207-217.	3.7	29
18	The Rational Use of Pituitary Stimulation Tests. <i>Deutsches Ärzteblatt International</i> , 2010, 107, 437-43.	0.9	29

#	ARTICLE	IF	CITATIONS
19	New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy. <i>Journal of Neuro-Oncology</i> , 2013, 114, 1-11.	2.9	28
20	Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I study. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1308-1317.	2.0	28
21	Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1017-1027.	2.0	27
22	Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas. <i>European Journal of Endocrinology</i> , 2009, 161, 747-753.	3.7	25
23	3 Rationale for treatment and therapeutic options in Cushing's disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, S15-S22.	4.7	24
24	Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study. <i>Clinical Endocrinology</i> , 2019, 91, 776-785.	2.4	24
25	Predictive factors for responses to primary medical treatment with lanreotide autogel 120mg in acromegaly: post hoc analyses from the PRIMARYS study. <i>Pituitary</i> , 2020, 23, 171-181.	2.9	22
26	Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers. <i>Pituitary</i> , 2015, 18, 245-252.	2.9	21
27	Treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature. <i>Clinical Endocrinology</i> , 2015, 82, 84-90.	2.4	21
28	MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis. <i>European Journal of Endocrinology</i> , 2019, 180, 155-164.	3.7	19
29	Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 365-374.	1.8	16
30	Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study. <i>Clinical Therapeutics</i> , 2012, 34, 677-688.	2.5	15
31	Biochemical diagnosis in prolactinomas: some caveats. <i>Pituitary</i> , 2020, 23, 9-15.	2.9	14
32	Biochemical diagnosis of Cushing's disease: Screening and confirmatory testing. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101519.	4.7	14
33	Diagnosis and management of prolactinomas: current challenges. <i>Pituitary</i> , 2020, 23, 1-2.	2.9	13
34	Diagnostic Value of Biochemical Parameters in the Differential Diagnosis of an Adrenal Mass. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 348-357.	3.8	9
35	Pituitary-directed medical therapy in Cushing's disease. <i>Pituitary</i> , 2015, 18, 238-244.	2.9	8
36	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2022, 25, 64-73.	2.9	7

#	ARTICLE	IF	CITATIONS
37	Neuroendocrine neoplasms “ still a challenge despite major advances in clinical care with the development of specialized guidelines. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 373-378.	5.7	6
38	How to manage pasireotide, when using as medical treatment for Cushing’s disease. <i>Endocrine</i> , 2015, 50, 526-528.	2.3	5
39	Overnight 1Âmg dexamethasone suppression test and 24Âh urine free cortisol’s accuracy and pitfalls when screening for Cushing’s syndrome. <i>Pituitary</i> , 2022, 25, 693-697.	2.9	2
40	Cushing disease: Where do we stand, where are we heading?. <i>Pituitary</i> , 2015, 18, 179-180.	2.9	1
41	Pituitary disease management during pregnancy: an overview. <i>Minerva Endocrinology</i> , 2018, 43, 420-422.	1.1	1
42	Secondary adrenal insufficiency in pregnancy: any differences?. <i>Minerva Endocrinology</i> , 2018, 43, 446-450.	1.1	1